Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Acrivon Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 55 | 1 | 55 | +1 |
| Shares | 23.5M | 767.0K | 23.0M | +275.9K (+1.2%) |
| Value | $136.1M | $4.45M | $160.8M | +$29.2M (+22.2%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 786,982 | $5.51M | 0.00% |
| Exome Asset Management LLC | 116,757 | $817.3K | 0.55% |
| Millennium Management LLC | 39,750 | $278.3K | 0.00% |
| Prelude Capital Management, LLC | 37,727 | $264.1K | 0.02% |
| Trexquant Investment LP | 30,383 | $212.7K | 0.00% |
| American Century Companies Inc | 15,402 | $107.8K | 0.00% |
| Sterling Capital Management LLC | 37 | $259 | 0.00% |
| Capital Performance Advisors LLP | 32 | $224 | 0.00% |
Sold out (7)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Paradigm Biocapital Advisors LP | 659,724 | $3.83M |
| Jane Street Group, LLC | 30,714 | $178.1K |
| Squarepoint Ops LLC | 17,207 | $99.8K |
| Walleye Capital LLC | 12,721 | $73.8K |
| Occudo Quantitative Strategies LP | 12,552 | $72.8K |
| XTX Topco Ltd | 10,493 | $60.9K |
| Advisor Group Holdings, Inc. | 5,080 | $29.5K |
Not filed for Q3 2024 yet (1)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 767,020 | $4.45M |